Neutralizing antibodies against SARS-CoV-2 of vaccinated healthcare workers in Taiwan.

Neutralizing antibodies against SARS-CoV-2 of vaccinated healthcare workers in Taiwan.

Publication date: Dec 01, 2025

Vaccination is one of the best ways to control the SARS-CoV-2 outbreak. In Taiwan, healthcare workers were prioritized for vaccination, but the effectiveness of these vaccines for them remains unclear. Thus, it’s essential to examine their neutralizing antibodies after prime-boost vaccinations. In this prospective observational study, 514 healthcare workers from Chang Gung Memorial hospitals in Taiwan were included between 19 March 2021 and 21 August 2021. The two doses of COVID-19 vaccines were either a match or a mixing of AZD1222 and mRNA-1273, e. g. AZD1222 + AZD1222 (n = 406), mRNA-1273 + mRNA-1273 (n = 62), and AZD1222 + mRNA-1273 (n = 46). Blood specimens were drawn after two doses of vaccines, defined as post-vaccine days [median 34. 00 days and interquartile range (IQR) 29. 00-42. 00 days], and examined for the neutralizing antibodies via SARS-CoV-2 neutralization kits. The results were analyzed as a percentage of inhibition based on the negative control. After 2 vaccination doses, subjects with AZD1222 + mRNA-1273 (median 97. 15%, IQR 96. 06-98. 06%) and mRNA-1273 + mRNA-1273 (median 97. 47%, IQR 96. 75-97. 89%) exhibited higher neutralizing antibodies than those receiving AZD1222 + AZD1222 vaccines (median 71. 28%, IQR 49. 39-89. 70%) (the percentage was referred to inhibition of surrogate virus). The post-vaccination days negatively impacted the neutralizing antibodies, except for the mRNA-1273 + mRNA-1273 group. The presence of fever, headache, and myalgia after the second dosage was reflected in the higher neutralizing antibodies (median of no fever 76. 00% vs. fever 97. 00%, p 

Concepts Keywords
August 2019-nCoV Vaccine mRNA-1273
Headache 2019-nCoV Vaccine mRNA-1273
Mrna Adult
Taiwan Antibodies, Neutralizing
Vaccinations Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
AZD1222
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Health Personnel
Humans
Male
Middle Aged
mRNA-1273
neutralizing antibody
Prospective Studies
SARS-CoV-2
SARS-CoV-2 vaccination
Taiwan
Taiwan healthcare workers
Vaccination

Semantics

Type Source Name
disease IDO blood
disease MESH COVID-19

Original Article

(Visited 2 times, 1 visits today)